Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells

International Journal of Oncology

Volumn 33, Issue 5, 2008, Pages 1107-1113

  Cunningham, Matthew P ^a   Thomas, Hilary ^a   Marks, Christopher ^b   Green, Margaret ^b   Fan, Zhen ^c   Modjtahedi, Helmout ^a,d  

^a Postgraduate Medical School   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; ICR62; Insulin like growth factor receptor I; NVP AEW541

Indexed keywords

ICR 62; MONOCLONAL ANTIBODY; NVP AEW 541; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NVP-AEW541; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SOMATOMEDIN B; SOMATOMEDIN C;

ARTICLE; CANCER CELL; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL PROLIFERATION; CELL STRAIN HCT116; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HCT116 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1;

EID: 58149183124     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000100     Document Type: Article

References (50)

1. Parkin DW: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
3. LeRoith D and Roberts CT: The insulin like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
4. Baserga R: Targeting the IGF-1 receptor: from rags to riches. Eur J Cancer 40: 2013-2015, 2004.
5. Butler AA, Yakar S, Gewolb IH, Karas M. Okubo Y and LeRoith D: Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol 121: 19-26, 1988.
6. Blakesley VA, Scrimgeour A, Esposito D and LeRoith D: Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev 7: 153-159, 1996.
7. Valentinis B and Baserga R: The IGF-I receptor protects tumour cells from apoptosis induced by high concentrations of serum. Biochem Biophys Res Commun 224: 362-368, 1996.
8. Rubini M, Hongo A, D'Ambrosio C and Baserga R: The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 230: 284-292, 1997.
9. Perer ES, Madan AK, Shurin A, et al: Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94: 1-5, 2000.
10. Peretz S, Kim C, Rockwell S, Baserga R and Glazer PM: IGF1 receptor expression protects against microenvironmental stress found in the solid tumour. Radiat Res 158: 174-180, 2002.
11. Reinmuth N, Fan F, Liu W, et al: Impact of insulin-like growth factor receptor-1 function on angiogenesis, growth and metastasis of colon cancer. Lab Invest 82: 1377-1389, 2002.
12. Sekharam M, Zhao H, Sun M, et al: Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 63: 7708-7716, 2003.
13. Hakam. A, Yeatman TJ, Lu L, et al: Expression of insulin-like growth factor-1 nsceptor in human colorectal cancer. Hum Pathol 30: 1128-1133, 1999.
14. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D and Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95: 2086-2095, 2002.
15. Ouban A, Muraca P, Yeatman T and Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803-808, 2003.
16. Peters G, Gongoll S, Langner C, et al: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal -cancer. Virchows Arch 443: 139-145, 2003.
17. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C and Modjtahedi H: Coexpression of the IGF-IR, EGFR, and HER-2 is common in colorectal cancer patients. Int J Oncol 28: 329-335, 2006.
18. Hailey J, Maxwell E, Koukouras K, Bishop WR Pachter JA and Wang Y: Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumour cells. Mol Cancer Ther 1: 1349-1353, 2002.
19. Jackson-Booth PG, Terry C, Lackey B, Lopaczynska M and Nissley P: Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res 35: 850-856, 2003.
20. Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63: 5073-5083, 2003.
21. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 5: 221-230, 2004.
22. Goetsch L, Gonzalez A, Leger O, et al: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316-328, 2005.
23. Min Y, Adachi Y, Yamamoto H, et al: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 54: 591-600, 2005.
24. Miyamoto S, Nakamura M, Shitara K, et al: Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 11: 3494-3502, 2005.
25. Warren RS, Yuan H, Matli MR, Ferrara N and Donner DB: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271: 29483-29488, 1996.
26. Liu B, Fang M, Lu Y, Mendelsohn J and Fan Z: Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20: 1913-1922, 2001.
27. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002.
28. Adams TE, McKern NM and Ward CW: Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 22: 89-95, 2004.
29. Wang D, Patil S, Li W, Humphrey LE, Brattain MG and Howell GM: Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21: 2785-2796, 2002.
30. Ahmad T, Farnie, G, Bundred NJ and Anderson NG: The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 279: 1713-1719, 2004.
31. Lu Y, Zi X, Zhao Y, Mascarenhas D and Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857, 2001.
32. Jones HE, Goddard L, Gee JM, et al: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814, 2004.
33. Camirand A, Zakikhani M, Young F and Pollak M: Inhibition of insulin like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7: 570-579, 2005.
34. Cunningham MP, Thomas H, Fan Z and Modjtahedi H: Responses of human colorectal tumour cells to treatment with anti-epidermal growth factor receptor antibody ICR62 used alone or in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 66: 7708-7715, 2006.
35. Garcia-Echeverria C, Pearson MA, Marti A, et al: In vivo antitumor activity of NVP-AEW541 - A novel, potent and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239, 2004.
36. Modjtahedi H, Styles JM and Dean CJ: The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67: 247-253, 1993.
37. Gross ME, Zorbas MA, Danels YJ, et al: Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51: 1452-1459, 1991.
38. Guvakova MA and Surmacz E: Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231: 149-162, 1997.
39. Lewis GD, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255-263, 1993.
40. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
41. Rocha-Lima CM, Soares HP, Raez LE and Singal R: EGFR targeting of solid tumours. Cancer Control 14: 295-304, 2007.
42. Ng K and Zhu AX: Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol 65: 8-20, 2008.
43. Hopfner M, Sutter AP, Huether A, Baradari V and Scherubl H: Tyrosine kinase of insulin growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 12: 5635-5643, 2006.
44. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.
45. Albanell J, Codony-Servat J, Rojo F, et al: Activated extra-cellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510, 2001.
46. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7: 31-39, 2002.
47. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A and Milella M: Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10: 81-100, 2007.
48. Wu X, Fan Z, Masui H, Rosen N and Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897-1905, 1995.
49. Modjtahedi H, Moscatello DK, Box G, et al: Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105: 273-2780, 2003.
50. Viloria-Petit, Crombet T, Jothy S, Hicklin D, Bohlen P, Schaeppi JM, Rak J and Kerbel RS: Acquired Resistance to the antitumour effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumour angiogenesis. Cancer Res 61: 5090-5101, 2001.